Received prior chemotherapy for any abdominal or pelvic tumor that include neoadjuvant chemotherapy (NACT) for ovarian, primary peritoneal or fallopian tube cancer
The study population will include women with a high preoperative suspicion of advanced primary epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (stage IIIC or IV) as determined by computed tomography (CT) or magnetic resonance imaging (MRI) of abdomen and pelvis planning to undergo exploratory laparotomy and surgical cytoreduction with the operative goal of this procedure to achieve optimal cytoreduction to less than  cm of residual disease
Platinum resistant Grade  or  ovarian, primary peritoneal or fallopian tube cancer
Histologic confirmation of ovarian, primary peritoneal or fallopian tube cancer of any subtype
Patient with primary or recurrent International Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian, fallopian tube, peritoneal carcinoma, or uterine cancer, confined to abdominal cavity, including those who have completed neoadjuvant chemotherapy and primary surgery
Preoperative or intraoperative (frozen section) diagnosis of ovarian, peritoneal, fallopian tubal or uterine cancer
Patients must have clinically and radiographically suspected and previously untreated International Federation of Gynecologic and Obstetrics (FIGO) stage III or IV epithelial ovarian, primary peritoneal or fallopian tube cancer, high grade, for whom the plan of management will include neoadjuvant chemotherapy (NACT) with interval tumor reductive surgery (TRS) who have undergone biopsies for histologic confirmation
For Part  Only: Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, or Triple Negative Breast Cancer with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v. in at least  lesion, that in the opinion of the Investigator is appropriate to treat with nab-paclitaxel.
Part : Ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancer
Measurable disease by physical exam or CT scan, or evaluable disease by CA-; (NOTE: CA--evaluable disease is defined as serum CA- >=  x ULN that is determined by the treating clinician to be due to recurrent ovarian, fallopian tube, or primary peritoneal cancer)
Eligible patients will be women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after chemotherapy with no evidence of disease or minimal residual disease for primary or recurrent disease; this may or may not be measurable; these patients would normally enter a period of observation after standard management
Patients with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer must have received at least one platinum-based chemotherapy regimen
Diagnosis of primary ovarian cancer of any histology (patients with diagnoses of fallopian tube and primary peritoneal cancer are also eligible), or primary uterine cancer of papillary serous histology
Platinum-refractory ovarian, fallopian tube, or primary peritoneal carcinoma
Patients must have clinically and radiographically suspected International Federation of Gynecology and Obstetrics (FIGO) stage  or  epithelial ovarian, primary peritoneal or fallopian tube cancer, high grade, for whom the plan of management will include neoadjuvant chemotherapy (NACT) with interval tumor reductive surgery (TRS); patients will be selected for NACT according to established criteria (Society of Gynecologic Oncology and the American Society of Clinical Oncology Guideline); patients must have undergone core needle biopsy for histologic confirmation prior to start of treatment
Patients with newly diagnosed advanced stage (III/IV) ovarian cancer (ovarian/fallopian tube/peritoneal cancer) who have been recommended to receive neoadjuvant carboplatin/paclitaxel chemotherapy with subsequent cytoreductive surgery
Prior treatment for ovarian, fallopian tube, or primary peritoneal cancer
Patients must have had one prior platinum-based chemotherapeutic regimen for management of ovarian, primary peritoneal, or fallopian tube carcinoma and at least two prior chemotherapy regimens
Subject has primary ovarian (including low malignant potential), fallopian tube, or primary peritoneal cancer Federation of Gynecology and Obstetrics (FIGO) stage III or IV defined surgically at the completion of initial abdominal surgery
Patients must have histologically or cytologically confirmed, known or highly suspected advanced (International Federation of Gynecology and Obstetrics [FIGO] stage II-IV) ovarian, primary peritoneal, or fallopian tube cancer, scheduled for primary or interval cytoreductive surgery
Patients must have received at least one-prior platinum based chemotherapy regimen, to include cisplatin, carboplatin or other organoplatinum compound, for treatment of primary or recurrent ovarian, fallopian tube or primary peritoneal cancer
Must have:\r\n* Recurrent or progressive ovarian cancer, primary peritoneal cancer or fallopian tube cancer after prior treatment with platinum and taxanes\r\n* Histologic confirmation of the original primary tumor\r\n* Prior bilateral oophorectomy
Diagnosis of Federation of Gynecology and Obstetrics (FIGO) stage III or grade IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma, has received at least  cycles of first line intravenous (IV)/IP cisplatin and paclitaxel chemotherapy and has stable disease or better as defined by measurable/evaluable tumor and/or CA- levels
Subjects with low-grade ovarian, fallopian tube, or Primary peritoneal cancer
Patients with clinical or surgical stage III or IV low-grade serous ovarian, primary peritoneal, or fallopian tube carcinomas who in the judgement of the treating physician are unlikely to achieve optimal surgical cytoreduction and have been recommended to receive neoadjuvant therapy.
Patients with low grade ovarian/fallopian tube/peritoneal cancers
Chemotherapy, hormonal, or biologic treatment for ovarian, fallopian tube, or primary peritoneal cancer in the last  days
Women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with platinum-resistant disease (defined as having relapsed within  months of last platinum-containing regimen because we would like to include both primary and secondary resistance); patients are allowed to have had more than  prior cytotoxic treatment regimens; all patients should have received standard of care agents, which confer clinical benefit
For ovarian, fallopian tube, and peritoneal cancers only: platinum-resistant, defined as =<  days from the date of the most recent dose of chemotherapy containing either carboplatin or cisplatin until the first evidence of cancer recurrence or progression either symptoms directly attributable to cancer, radiographic recurrence of cancer, or cancer antigen  (CA-) > , confirmed >=  days later (confirmation of elevated CA- may be beyond  days and still count as platinum-resistant)
Patients with histologically proven stage III or IV ovarian, fallopian tube or primary peritoneal serous carcinoma (or patients of any stage with recurrent disease) who demonstrate lack of disease progression as determined by clinical assessment as well as cancer antigen  (CA-) levels and/or radiographic assessment
Patients who have undergone therapeutic debulking surgery for independent clinical indications and have tissue frozen and stored under sterile conditions as part of protocol - (Study of Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer)
Patients who have received prior chemotherapy for any abdominal or pelvic tumor (other than ovarian, fallopian tube, and primary peritoneal) are excluded
Phase : Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within  months from completion of platinum-based chemotherapy).
Phase : Individuals with epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinomas who are considered to have platinum-resistant disease (progression within  months from completion of a minimum of  platinum therapy cycles).
Pathologic diagnosis of ovarian, fallopian tube or primary peritoneal cancer confirmed by pathology review at Memorial Sloan Kettering (MSK)
Histologically or cytologically confirmed primary disease histology of solid ovarian, fallopian tube, or primary peritoneal tumor categorization
Any histologically confirmed locally advanced recurrent endometrial adenocarcinoma (except for carcinosarcoma), recurrent high-grade serous ovarian/primary peritoneal/fallopian tube carcinoma, or deleterious BRCA mutant recurrent ovarian/primary peritoneal/fallopian tube cancer for whom no curative option is available will be eligible; any patient proven to have metastatic triple negative breast cancer, defined from standard pathologic assays as negative for estrogen receptor (ER) and progesterone receptor (PR) (< % tumor staining) will be eligible
Subjects with histologic diagnosis of epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma, following initial surgery; all subjects must have had appropriate surgery for ovarian, primary peritoneal, or fallopian tube carcinoma with appropriate tissue available for histologic evaluation to confirm diagnosis and stage; pathology must be verified at Memorial Sloan-Kettering Cancer Center; patients with initial cytoreduction surgery performed at outside hospitals will be eligible for this protocol
Patients who have previously been diagnosed and treated for earlier stage ovarian, fallopian tube or primary peritoneal cancer.
Have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer
Have been previously treated with Gemcitabine for ovarian, fallopian tube or primary peritoneal cancer
Patients with biopsy proven stage IIIC/IV epithelial ovarian cancer, primary peritoneal, fallopian tube carcinoma; if a core biopsy is not possible, fine-needle aspirate showing adenocarcinoma is acceptable in the setting of a pelvic mass and presence of metastasis outside the pelvis measuring at least  cm, regional lymph-node metastasis or proof of stage IV disease, and ratio of cancer antigen (CA)  to carcinoembryonic antigen (CEA) greater than ; if CA  to CEA ratio is  or lower, barium enema, gastroscopy, and mammography must be negative
Patients assumed to have a borderline malignancy of the ovary, fallopian tube, or primary peritoneal cancer
Patients who receive neoadjuvant chemotherapy for their ovarian, primary peritoneal, or fallopian tube cancer
Patients who have received targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their primary peritoneal, ovarian, or fallopian tube cancer
Metastases to the ovaries from other organs except fallopian tube or primary peritoneal carcinoma
Subject has recurrent ovarian (including low malignant potential), fallopian tube or primary peritoneal cancer
Patients with a histologic diagnosis of epithelial ovarian cancer, peritoneal primary carcinoma or fallopian tube cancer; FIGO stage III and IV defined surgically at the completion of initial abdominal surgery and with appropriate tissue available for histologic evaluation. The minimum surgery required is an abdominal surgery providing tissue for histologic evaluation and establishing and documenting the primary site and stage, as well as a maximal effort at tumor debulking.
Women with suspected epithelial ovarian, fallopian tube or primary peritoneal carcinoma scheduled to undergo surgical exploration with no prior treatment for the cancer; signs of ovarian cancer include, but are not limited to: an elevated CA, a complex pelvic mass, ascites, and carcinomatosis; these signs are not necessary for suspicion or enrollment in this protocol
Histologically documented ovarian, primary peritoneal or fallopian tube cancer
Histologically diagnosed ovarian cancer, fallopian tube cancer or primary peritoneal cancer
Subjects must have cytologically or histologically confirmed ovarian, primary peritoneal or fallopian tube cancer.. In addition, subjects must have a tumor that is at least  cm in a single dimension and is radiographically apparent on CT, PET-CT or MRI (i.e., RECIST version . measurable disease).
Patients must be suspected of having a diagnosis of ovarian, fallopian tube or primary peritoneal cancer with a planned cytoreductive surgery
Up to  patients with histological or cytological documentation of advanced ovarian, fallopian tube, or primary peritoneal carcinoma with a history of progression or recurrence following at least one prior platinum and one taxane based chemotherapy
Women with stages II-IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have completed standard therapy for primary or recurrent disease (i.e., patients who would normally be observed); eligible patients may have asymptomatic residual measurable disease on physical examination and/or computed tomography (CT) scan, and/or may have an elevated cancer antigen  (CA-); or may be in complete clinical remission after treatment for primary or recurrent disease; these patients would normally enter a period of observation after standard management
Diagnosis of stage III, IV or recurrent gynecologic malignancy (uterine, ovarian, cervical, vulvar, vaginal, fallopian tube, primary peritoneal)
Woman diagnosed with ovarian, primary peritoneal or fallopian tube cancer
Have had ovarian cancer or fallopian tube cancer at any age
Newly diagnosed with any stage of primary ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer in the past  months
Patients with an initial diagnosis of ovarian, fallopian tube or primary peritoneal cancer who completed primary ovarian cancer surgery or  cycles of neoadjuvant chemotherapy with interval cytoreductive surgery (ICS)
Final pathologic diagnosis of stage I-IV ovarian, primary peritoneal or fallopian tube cancer with plan to receive primary adjuvant chemotherapy or completion of chemotherapy after ICS
Undergoing surgical management for a suspected diagnosis of gynecologic malignancy (endometrial, ovarian, vulvar, vaginal, primary peritoneal, fallopian tube)
Patients with any stage epithelial ovarian cancer, including cancers arising from the fallopian tube and primary peritoneal cancer, or patients with other gynecologic malignancy (any stage), who are chemotherapy-naive, and scheduled to undergo at least  cycles of intravenous platinum/taxane-based chemotherapy
Patients who are currently undergoing treatment (primary or consolidation) for stage II, III or IV ovarian, fallopian tube or primary peritoneal cancer or who completed treatment less than six weeks ago
Women with a personal history of ovarian, fallopian tube, or primary peritoneal cancer
Presence of at least one fallopian tube; prior tubal ligation is allowed
Women with a history of ovarian, fallopian tube, or primary peritoneal cancer
Prior treatment for ovarian, fallopian tube, or primary peritoneal cancer
Patients must be suspected of having a diagnosis of ovarian, fallopian tube or primary peritoneal cancer with a planned cytoreductive surgery
Prior treatment for ovarian, fallopian tube, or primary peritoneal cancer
Histologically confirmed Epitheilial Ovarian Cancer (EOC), Fallopian Tube Cancer (FTC) or Primary Peritoneal Cancer (PPC).
